Zealand Pharma A/S (OTCMKTS:ZLDPF) Downgraded to “Hold” Rating by Berenberg Bank

Zealand Pharma A/S (OTCMKTS:ZLDPF) was downgraded by equities researchers at Berenberg Bank from a “strong-buy” rating to a “hold” rating in a report issued on Wednesday,Zacks.com reports.

A number of other equities analysts have also weighed in on the stock. William Blair reiterated a “market perform” rating on shares of Zealand Pharma A/S in a research report on Friday, March 6th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating on shares of Zealand Pharma A/S in a research report on Thursday, June 4th. BNP Paribas Exane lowered shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Friday, March 6th. Cantor Fitzgerald reiterated a “neutral” rating on shares of Zealand Pharma A/S in a research report on Friday, March 6th. Finally, Wolfe Research lowered shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Thursday, June 11th. Three analysts have rated the stock with a Strong Buy rating and seven have assigned a Hold rating to the stock. According to MarketBeat, Zealand Pharma A/S has an average rating of “Moderate Buy”.

Zealand Pharma A/S Stock Performance

Shares of Zealand Pharma A/S stock opened at $45.01 on Wednesday. The company has a quick ratio of 37.17, a current ratio of 37.17 and a debt-to-equity ratio of 0.02. The firm has a market capitalization of $3.22 billion, a P/E ratio of 3.34 and a beta of 0.86. The firm’s 50 day moving average is $47.90 and its two-hundred day moving average is $57.22. Zealand Pharma A/S has a 52 week low of $35.93 and a 52 week high of $83.12.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last announced its earnings results on Thursday, May 7th. The company reported ($0.87) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.37) by $0.50. The business had revenue of $5.33 million for the quarter, compared to analyst estimates of $2.81 million. Zealand Pharma A/S had a net margin of 68.82% and a return on equity of 41.80%. Research analysts forecast that Zealand Pharma A/S will post 2.37 EPS for the current fiscal year.

About Zealand Pharma A/S

Zealand Pharma A/S is a Denmark?based biopharmaceutical company specializing in the discovery, design and development of peptide?based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.